Astria Therapeutics' (ATXS) shares were up nearly 3% in recent Friday trading after JMP Securities initiated the company's stock at outperform.
This comes days after the company started its phase 1a clinical trial in healthy subjects of STAR-0310, a potential treatment for atopic dermatitis. Early proof-of-concept results are expected in Q3.
Trading volume stood at over 162,000 shares against a daily average of about 323,000 shares.
Price: 7.70, Change: +0.21, Percent Change: +2.80
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。